Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
AN2 Therapeutics Inc (ANTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: ANTX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -44.14% | Avg. Invested days 35 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 42.78M USD | Price to earnings Ratio - | 1Y Target Price 2.67 |
Price to earnings Ratio - | 1Y Target Price 2.67 | ||
Volume (30-day avg) 127035 | Beta 0.14 | 52 Weeks Range 0.87 - 3.54 | Updated Date 04/1/2025 |
52 Weeks Range 0.87 - 3.54 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.72 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -29.54% | Return on Equity (TTM) -49.69% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -55213703 | Price to Sales(TTM) - |
Enterprise Value -55213703 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.11 | Shares Outstanding 30098700 | Shares Floating 17732962 |
Shares Outstanding 30098700 | Shares Floating 17732962 | ||
Percent Insiders 22.34 | Percent Institutions 45.97 |
Analyst Ratings
Rating 2.8 | Target Price 2.67 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold 3 | Sell - | Strong Sell 1 | |
Strong Sell 1 |
Upturn AI SWOT
AN2 Therapeutics Inc
Company Overview
History and Background
AN2 Therapeutics, Inc. (ANTX) is a biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with unmet needs. It was founded in 2018. Key milestones include progressing their lead candidate, epetraborole, through clinical trials for treatment-refractory Mycobacterium avium complex (MAC) lung disease.
Core Business Areas
- Infectious Disease Therapeutics: Focuses on the development and commercialization of novel therapies to address unmet medical needs in the treatment of rare and chronic infectious diseases.
Leadership and Structure
The leadership team includes prominent figures in the pharmaceutical industry with experience in drug development and commercialization. Structure is typical of a clinical-stage biotech company.
Top Products and Market Share
Key Offerings
- Epetraborole: Epetraborole is AN2 Therapeutics' lead product candidate, an antibacterial small molecule being developed for the treatment of treatment-refractory Mycobacterium avium complex (MAC) lung disease. There is currently no reliable market share data available. Competitors include pharmaceutical companies developing treatments for MAC, although epetraborole targets treatment-refractory cases.
Market Dynamics
Industry Overview
The pharmaceutical industry for infectious diseases is driven by increasing antibiotic resistance and the need for novel therapies to address persistent and emerging pathogens.
Positioning
AN2 Therapeutics is positioned as a company focused on developing therapies for rare and neglected infectious diseases with unmet needs. Their focus on treatment-refractory MAC lung disease offers a niche opportunity.
Total Addressable Market (TAM)
The global MAC lung disease market is estimated to be hundreds of millions of dollars, and AN2 is positioned to capture a portion of this market, primarily in the treatment-refractory segment. TAM estimates vary depending on sources and disease prevalence.
Upturn SWOT Analysis
Strengths
- Novel drug candidate targeting a specific unmet medical need.
- Experienced management team.
- Focus on rare and neglected infectious diseases can lead to expedited regulatory pathways.
Weaknesses
- Single product pipeline creates high reliance on epetraborole's success.
- Clinical stage company with no currently marketed products and no revenue.
- Requires significant capital investment for ongoing research and development, manufacturing and regulatory approvals.
Opportunities
- Potential for accelerated approval pathways due to unmet medical need.
- Expansion of pipeline through acquisitions or in-licensing.
- Partnerships with larger pharmaceutical companies for development and commercialization.
Threats
- Clinical trial failures for epetraborole.
- Competition from existing therapies or novel treatments developed by other companies.
- Regulatory hurdles and delays in approval process.
- Difficulty raising capital to fund operations.
Competitors and Market Share
Key Competitors
- GILD
- ABBV
- PFE
Competitive Landscape
AN2 Therapeutics is a small player compared to established pharmaceutical companies. Their competitive advantage lies in their novel treatment approach for treatment-refractory MAC lung disease. Competition includes companies with broad portfolios targeting infectious diseases.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited, given the company's recent founding and clinical-stage status.
Future Projections: Future growth depends on the successful development and commercialization of epetraborole.
Recent Initiatives: Focusing on completion of clinical trials and seeking potential partnerships.
Summary
AN2 Therapeutics is a high-risk, high-reward clinical-stage biopharmaceutical company. Its success hinges on the successful development and commercialization of epetraborole. The company needs to effectively manage its cash runway and navigate regulatory hurdles. The lack of diversified pipeline is a significant concern for investors.
Similar Companies
- VIR
- IDXX
- RVMD
- AGEN
Sources and Disclaimers
Data Sources:
- AN2 Therapeutics Investor Relations
- SEC Filings
- Industry Reports
- Financial News Outlets
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About AN2 Therapeutics Inc
Exchange NASDAQ | Headquaters Menlo Park, CA, United States | ||
IPO Launch date 2022-03-25 | Co-Founder, CEO, President & Chairman of the Board Mr. Eric E. Easom | ||
Sector Healthcare | Industry Biotechnology | Full time employees 22 | Website https://www.an2therapeutics.com |
Full time employees 22 | Website https://www.an2therapeutics.com | ||
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, which is in a pivotal Phase 2/3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease. The company also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize, or otherwise exploit certain compounds and products, including epetraborole, for the treatment, diagnosis, or prevention of all human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize certain compounds and products, including epetraborole, in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.